Obinutuzumab exposure during early twin pregnancy in antisynthetase syndrome with interstitial lung disease

This is the authors' abstract. We don't add key points for this paper.

Antisynthetase syndrome (anti–Jo-1 positive) with inflammatory myopathy and interstitial lung disease (ILD) poses substantial challenges in pregnancy, particularly in patients with severe, treatment-refractory disease[1]. We report the first case of obinutuzumab administered during early pregnancy in a high-risk twin gestation, resulting in sustained maternal disease control and reassuring short-term neonatal outcomes.